Show simple item record

AuthorChemaitelly, Hiam
AuthorAyoub, Houssein H.
AuthorAlMukdad, Sawsan
AuthorFaust, Jeremy S.
AuthorTang, Patrick
AuthorCoyle, Peter
AuthorYassine, Hadi M.
AuthorAl Thani, Asmaa A.
AuthorAl-Khatib, Hebah A.
AuthorHasan, Mohammad R.
AuthorAl-Kanaani, Zaina
AuthorAl-Kuwari, Einas
AuthorJeremijenko, Andrew
AuthorKaleeckal, Anvar H.
AuthorLatif, Ali N.
AuthorShaik, Riyazuddin M.
AuthorAbdul-Rahim, Hanan F.
AuthorNasrallah, Gheyath K.
AuthorAl-Kuwari, Mohamed G.
AuthorButt, Adeel A.
AuthorAl-Romaihi, Hamad E.
AuthorAl-Thani, Mohamed H.
AuthorAl-Khal, Abdullatif
AuthorBertollini, Roberto
AuthorAbu-Raddad, Laith J.
Available date2023-09-26T06:01:42Z
Publication Date2023-09-05
Publication NameJournal of travel medicine
Identifierhttp://dx.doi.org/10.1093/jtm/taad106
CitationHiam Chemaitelly, Houssein H Ayoub, Sawsan AlMukdad, Jeremy S Faust, Patrick Tang, Peter Coyle, Hadi M Yassine, Asmaa A Al Thani, Hebah A Al-Khatib, Mohammad R Hasan, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, Anvar H Kaleeckal, Ali N Latif, Riyazuddin M Shaik, Hanan F Abdul-Rahim, Gheyath K Nasrallah, Mohamed G Al-Kuwari, Adeel A Butt, Hamad E Al-Romaihi, Mohamed H Al-Thani, Abdullatif Al-Khal, Roberto Bertollini, Laith J Abu-Raddad, Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections, Journal of Travel Medicine, Volume 30, Issue 5, July 2023, taad106, https://doi.org/10.1093/jtm/taad106
ISSN1195-1982
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85169846797&origin=inward
URIhttp://hdl.handle.net/10576/47962
AbstractIn October of 2022, Qatar introduced COVID-19 bivalent vaccination for persons ≥ 12 years using the 50-μg mRNA-1273.214 vaccine combining SARS-CoV-2 ancestral and omicron BA.1 strains.1 We estimated this vaccine’s effectiveness against SARS-CoV-2 infection. Using Qatar’s national SARS-CoV-2 databases, we conducted a matched, retrospective, cohort study to compare infection incidence in the national cohort of persons who received the vaccine (bivalent cohort) to that in the national cohort of Qatar residents whose last vaccination was ≥6 months before follow-up start (no-recent-vaccination cohort; Supplementary Appendix 1). The 6-month cut-off was chosen because of negligible effectiveness of first-generation vaccines against omicron infection ≥ 6 months after vaccination.2 Incidence of infection was defined as the first SARS-CoV-2 PCR-positive or rapid-antigen-positive test after the start of follow-up, regardless of symptoms. Cohorts were balanced on observed confounders through exact matching. Follow-up started 7 days after the person in the bivalent cohort received their vaccine dose. Associations were estimated using Cox proportional-hazards models adjusted for the matching factors and testing rate.
Languageen
Subjectasymptomatic infection
Hybrid immunity
natural infection
Qatar
variant-containing COVID-19 vaccines
waning vaccine effectiveness
TitleBivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections
TypeArticle
Issue Number5
Volume Number30
ESSN1708-8305
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record